Integrilin

Roman name

Integrilin #

The composition and the form of

1 ml for injections or infusions of eptifibatida 2, or 0.75 mg respectively; in the bottle for 10 or 100 ml.

Of drugs

Antiagregatine. Warn tying fibrinoguena factor Villebranda etc. adgeziveh ligands with glikoproteinovmi IIb / IIIa receptor count.

Indications

The acute coronary syndrome : unstable stenocardia, myocardial infarction without zubza Q (prevention of deaths and re-myocardial infarction); The transluminalna percutaneous coronary angioplastiki - CTKA (prevention tromboticescoy occluzii artery diseases and acute ischaemic complications, death, myocardial infarction).

Pregnancy and lactation

Perhaps if the effect of therapy outweighs the potential risk to the fetus or child.

Contraindications

Гиперчувствительност ь to any of the product components; diates bloody in the history or expressed pathological bleeding in the past 30 days, expressed arterial hypertension (Sad above 200 mm.rt.st. or Dad above mm.rt.st. 110), while antigipertenzivna therapy; more surgery in the previous six weeks, stroke in the previous 30 days or haemorrhagic stroke (in history), the ongoing or planned use other receptors inhibitor IIb / IIIa for injecting, dependence on dialysis due to renal failure.

Side-Effects

Most are small hemorrhages (macrogematuria, gematemezis), at-large bleeding, including life-threatening (and gastrointestinal bleeding lung). In rare cases, anaemia.

Precautions

Be wary appointed to increased risk of bleeding, including in old age and low body weight. Continuous monitoring of sites of possible bleeding, including place a catheter, the arterial, venous or Puncture (risk of bleeding highest in the field of arterial access in CTKA). When it is necessary to carry out emergency or planned surgery infuziu drug cease. It should refrain from the use of drugs in paediatric practice, since safety and efficacy of their use in children has not been quantified.

Dosing and Administration

A typically in conjunction with aspirin and Geparinom.ostry coronary syndrome. B / bolusno to 180 µ g / kg, followed by a continuous infusions to 2 µ g / kg / min (in the level of serum creatinine below 2 mg / cm), or 1 µ g / kg / min (in the level of serum creatinine 2-4 mg / m) for up to 72 h (or before discharge from the hospital if it is sooner). In the case of a patient CTKA on urgent testimony infuziu should continue for the next 18 to 24 hours after the intervention (maximum total duration of therapy, 96 h). CTKA. Before manipulation / in bolusno 180 µ g / kg followed by a continuous infusions to 2 µ g / kg / min (in the level of serum creatinine below 2 mg / cm), or 1 µ g / kg / min (in the level of serum creatinine 2-4 mg / cm), 10 min impose additional 180 µ g / kg in the form of bolusa. Infuziu continue for 18-24 hours, or until the patient discharge from the hospital if it is sooner, but not less than 12 hours

Storage conditions

r-r d / inf. : In the dark place at a temperature of 2-8 ° Cr-r d / in. : In the dark place at a temperature of 2-8 ° C

Shelf life

r-r d / inf. : 3 gu.r-r d / in. : 3 and

Directory → Gematotropona funds → Antiagreganta → Integrilin